Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2007 1
2008 1
2009 3
2010 3
2011 2
2012 1
2013 1
2015 1
2017 1
2018 1
2019 1
2020 1
2021 2
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

18 results
Results by year
Filters applied: . Clear all
Page 1
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism.
Vaseva AV, Blake DR, Gilbert TSK, Ng S, Hostetter G, Azam SH, Ozkan-Dagliyan I, Gautam P, Bryant KL, Pearce KH, Herring LE, Han H, Graves LM, Witkiewicz AK, Knudsen ES, Pecot CV, Rashid N, Houghton PJ, Wennerberg K, Cox AD, Der CJ. Vaseva AV, et al. Cancer Cell. 2018 Nov 12;34(5):807-822.e7. doi: 10.1016/j.ccell.2018.10.001. Cancer Cell. 2018. PMID: 30423298 Free PMC article.
The mitochondrial p53 pathway.
Vaseva AV, Moll UM. Vaseva AV, et al. Biochim Biophys Acta. 2009 May;1787(5):414-20. doi: 10.1016/j.bbabio.2008.10.005. Epub 2008 Oct 25. Biochim Biophys Acta. 2009. PMID: 19007744 Free PMC article. Review.
Identification of p53 in mitochondria.
Vaseva AV, Moll UM. Vaseva AV, et al. Methods Mol Biol. 2013;962:75-84. doi: 10.1007/978-1-62703-236-0_6. Methods Mol Biol. 2013. PMID: 23150438
SNAI2-Mediated Repression of BIM Protects Rhabdomyosarcoma from Ionizing Radiation.
Wang L, Hensch NR, Bondra K, Sreenivas P, Zhao XR, Chen J, Moreno Campos R, Baxi K, Vaseva AV, Sunkel BD, Gryder BE, Pomella S, Stanton BZ, Zheng S, Chen EY, Rota R, Khan J, Houghton PJ, Ignatius MS. Wang L, et al. Among authors: vaseva av. Cancer Res. 2021 Nov 1;81(21):5451-5463. doi: 10.1158/0008-5472.CAN-20-4191. Epub 2021 Aug 30. Cancer Res. 2021. PMID: 34462275
Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer.
Blake DR, Vaseva AV, Hodge RG, Kline MP, Gilbert TSK, Tyagi V, Huang D, Whiten GC, Larson JE, Wang X, Pearce KH, Herring LE, Graves LM, Frye SV, Emanuele MJ, Cox AD, Der CJ. Blake DR, et al. Among authors: vaseva av. Sci Signal. 2019 Jul 16;12(590):eaav7259. doi: 10.1126/scisignal.aav7259. Sci Signal. 2019. PMID: 31311847 Free PMC article.
Repression of cyclin D1 as a target for germ cell tumors.
Freemantle SJ, Vaseva AV, Ewings KE, Bee T, Krizan KA, Kelley MR, Hattab EM, Memoli VA, Black CC, Spinella MJ, Dmitrovsky E. Freemantle SJ, et al. Among authors: vaseva av. Int J Oncol. 2007 Feb;30(2):333-40. Int J Oncol. 2007. PMID: 17203214
Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma.
Garcia N, Del Pozo V, Yohe ME, Goodwin CM, Shackleford TJ, Wang L, Baxi K, Chen Y, Rogojina AT, Zimmerman SM, Peer CJ, Figg WD, Ignatius MS, Wood KC, Houghton PJ, Vaseva AV. Garcia N, et al. Among authors: vaseva av. Mol Cancer Ther. 2022 Jan;21(1):170-183. doi: 10.1158/1535-7163.MCT-21-0194. Epub 2021 Nov 4. Mol Cancer Ther. 2022. PMID: 34737198
Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies.
Waters AM, Ozkan-Dagliyan I, Vaseva AV, Fer N, Strathern LA, Hobbs GA, Tessier-Cloutier B, Gillette WK, Bagni R, Whiteley GR, Hartley JL, McCormick F, Cox AD, Houghton PJ, Huntsman DG, Philips MR, Der CJ. Waters AM, et al. Among authors: vaseva av. Sci Signal. 2017 Sep 26;10(498):eaao3332. doi: 10.1126/scisignal.aao3332. Sci Signal. 2017. PMID: 28951536 Free PMC article.
18 results